From 57ff8d9b6d30654ff8d44e6f794411d01addaf31 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 16 Mar 2026 14:37:40 +0000 Subject: [PATCH] extract: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare Pentagon-Agent: Ganymede --- ...t cost impact inflationary through 2035.md | 6 ++++ ...ients-undermining-chronic-use-economics.md | 6 ++++ ...just-clinical-factors-drive-persistence.md | 6 ++++ ...-novo-lilly-glp1-price-deals-medicare.json | 32 +++++++++++++++++++ ...mp-novo-lilly-glp1-price-deals-medicare.md | 15 ++++++++- 5 files changed, 64 insertions(+), 1 deletion(-) create mode 100644 inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index ff0765e39..8571e26e9 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -47,6 +47,12 @@ MASH/NASH is projected to become the leading cause of liver transplantation. GLP The BALANCE Model directly addresses the chronic use inflation problem by requiring lifestyle interventions alongside medication. If lifestyle supports can sustain metabolic benefits after medication discontinuation, the model could demonstrate a pathway to positive net cost impact. The 6-year test window (through 2031) will provide empirical data on whether combined intervention changes the chronic use economics. + +### Additional Evidence (challenge) +*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* + +The Trump administration Medicare deal establishes $245/month pricing (82% below list) with narrow eligibility targeting high-risk comorbid patients (~10% of Medicare beneficiaries). This fundamentally changes the cost-effectiveness calculation: the 'inflationary through 2035' conclusion assumed higher prices and broader population. With narrow targeting to patients showing strongest evidence for downstream savings (kidney disease, cardiovascular, heart failure) and 82% price reduction, the net cost impact under capitated MA plans may be neutral or positive rather than inflationary. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 1f412e7f8..571816e08 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design. + +### Additional Evidence (extend) +*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* + +The Medicare deal includes $50/month out-of-pocket maximum for tirzepatide starting April 2026, removing the primary financial barrier to persistence. Lower-income patients show higher discontinuation rates, suggesting affordability drives persistence more than previously understood. The $50 OOP cap may substantially improve the 15% two-year persistence rate by eliminating cost as a discontinuation factor. + --- Relevant Notes: diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index c8aa03417..d11d382a1 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se. + +### Additional Evidence (confirm) +*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* + +The Medicare deal's $50/month OOP cap explicitly addresses affordability as a persistence barrier. The deal structure (steep price reduction + low OOP cap) suggests policymakers view affordability as the primary persistence obstacle for Medicare beneficiaries, confirming that discontinuation is driven by cost rather than clinical factors. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json b/inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json new file mode 100644 index 000000000..125cac481 --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "manufacturer-price-concessions-in-exchange-for-coverage-expansion-bypasses-traditional-cms-rulemaking-as-novel-policy-mechanism.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md:set_created:2026-03-16", + "manufacturer-price-concessions-in-exchange-for-coverage-expansion-bypasses-traditional-cms-rulemaking-as-novel-policy-mechanism.md:set_created:2026-03-16" + ], + "rejections": [ + "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md:missing_attribution_extractor", + "manufacturer-price-concessions-in-exchange-for-coverage-expansion-bypasses-traditional-cms-rulemaking-as-novel-policy-mechanism.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md b/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md index 4b112ae56..66b609f60 100644 --- a/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md +++ b/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md @@ -7,9 +7,13 @@ date: 2025-11-06 domain: health secondary_domains: [internet-finance] format: news -status: unprocessed +status: enrichment priority: high tags: [glp-1, drug-pricing, medicare, policy, trump-administration, market-structure] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -45,3 +49,12 @@ On November 6, 2025, President Trump announced agreements with Eli Lilly and Nov PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: The price reduction + coverage expansion + narrow eligibility criteria fundamentally change the economics analyzed in the existing claim — the "inflationary through 2035" conclusion assumed higher prices and broader population EXTRACTION HINT: Focus on how narrow eligibility (comorbid patients only) changes the cost-effectiveness calculus vs. broad population coverage + + +## Key Facts +- Medicare GLP-1 payment demonstration begins July 2026 +- BALANCE Model in Medicaid begins May 2026 +- BALANCE Model in Medicare Part D begins January 2027 +- Oral Wegovy launches January 2026 at $149-$299/month +- Medicare beneficiaries pay $50/month OOP maximum for tirzepatide starting April 2026 +- Approximately 10% of Medicare beneficiaries expected to be eligible under comorbidity criteria